• Users Online: 519
  • Home
  • Print this page
  • Email this page
Home Current issue Ahead of print Search About us Editorial board Archives Submit article Instructions Subscribe Contacts Login 
Year : 2013  |  Volume : 106  |  Issue : 2  |  Page : 85-91

Comparing the combined effect of triamcinolone with bevacizumab with bevacizumab alone in neovascular age-related macular degeneration

Ophthalmology Center, Faculty of Medicine, Mansoura University, Mansoura, Egypt

Correspondence Address:
Abeer M Khattab
MD, Ophthalmology Center, Faculty of Medicine, Mansoura University, Mansoura
Login to access the Email id

Source of Support: None, Conflict of Interest: None

DOI: 10.7123/01.JEO.0000431544.72499.fc

Rights and Permissions


To compare the short-term outcomes of intravitreal bevacizumab alone with the combination of intravitreal bevacizumab and intravitreal triamcinolone acetonide for the treatment of neovascular age-related macular degeneration (AMD).

Patients and methods

This randomized clinical trial was conducted on 48 eyes of 48 patients with subfoveal and juxtafoveal choroidal neovascularization secondary to AMD. The eyes were randomly assigned to receive combined intravitreal bevacizumab 1.25 mg with intravitreal triamcinolone acetonide 4 mg (group 1, 24 eyes) or intravitreal bevacizumab alone (group 2, 24 eyes). Assessment of best-corrected visual acuity (BCVA), optical coherence tomography, was carried out at baseline and repeated at all postoperative follow-up intervals (1 week, 1 month, 3 months, and 6 months) and fluorescein angiography was performed at baseline and repeated 1 month after treatment.


The mean age of the patients was 60.83±6.32 years (range 50–70 years) and 50.0% of the patients were men in group 1. In group 2, the mean age of the patients was 58.33±6.49 years (range 50–72 years) and there were 13 men (54.2%). BCVA improved from 0.13±0.06 (range 0.103–0.152) to 0.23±0.13 (range 0.175–0.287) (P=0.00) in group 1 whereas in group 2, no improvement in BCVA occurred as the baseline was 0.23±0.14 (range 0.167–0.286) and it was 0.21±012 (range 0.167–0.267) at the end of the follow-up (6 months) (P=0.00). Mean±SD central macular thickness at baseline was 363.708±70.115 μm (range 332–420 μm) and reduced to 287.958±21.497 μm (range 250–317 μm) at 6 months postoperatively in group 1 (P=0.00). However, in group 2, the mean±SD central macular thickness at baseline was 334.5±28.537 μm (range 305–410 μm) and moderately reduced to 304.25±23.265 μm (range 268–360 μm) at 6 months (P=0.04).


The addition of triamcinolone acetonide to bevacizumab for the treatment of neovascular AMD seems to increase its short-term efficacy significantly.

Print this article     Email this article
 Next article
 Previous article
 Table of Contents

 Similar in PUBMED
   Search Pubmed for
   Search in Google Scholar for
 Related articles
 Citation Manager
 Access Statistics
 Reader Comments
 Email Alert *
 Add to My List *
 * Requires registration (Free)

 Article Access Statistics
    PDF Downloaded84    
    Comments [Add]    

Recommend this journal